| Literature DB >> 13677481 |
Paul J Lewi1, Marc de Jonge, Frits Daeyaert, Luc Koymans, Maarten Vinkers, Jan Heeres, Paul A J Janssen, Eddy Arnold, Kalyan Das, Art D Clark, Stephen H Hughes, Paul L Boyer, Marie-Pierre de Béthune, Rudi Pauwels, Koen Andries, Mike Kukla, Donald Ludovici, Bart De Corte, Robert Kavash, Chih Ho, Paul J Lewis.
Abstract
There are several indications that a given compound or a set of related compounds can bind in different modes to a specific binding site of a protein. This is especially evident from X-ray crystallographic structures of ligand-protein complexes. The availability of multiple binding modes of a ligand in a binding site may present an advantage in drug design when simultaneously optimizing several criteria. In the case of the design of anti-HIV compounds we observed that the more active compounds that are also resilient against mutation of the non-nucleoside binding site of HIV1-reverse transcriptase make use of more binding modes than the less active and resilient compounds.Entities:
Mesh:
Substances:
Year: 2003 PMID: 13677481 DOI: 10.1023/a:1025313705564
Source DB: PubMed Journal: J Comput Aided Mol Des ISSN: 0920-654X Impact factor: 3.686